最新消息
I-Mab to Report Full Year 2022 Financial Results and Provide Corporate Update on March 31, 2023
2023.03.20
GAITHERSBURG, Md. and SHANGHAI, China , March 20, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results
In light of the recent development of the Silicon Valley Bank (the “SVB”), I-Mab (the “Company”) today issued a statement confirming that the Company does not hold any cash deposits at SVB or its affiliates, and has no exposure to or business dealings with SVB or its affiliates.
MSCI ESG Updated I-Mab to "A" Rating
2023.03.07
GAITHERSBURG, MD . and SHANGHAI , March 7, 2023 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB ), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that I-Mab has been granted "A" rating by MSCI (